Viewing StudyNCT03647488

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 11:58 AM
Last Modification Date: 2024-10-26 @ 12:52 PM
Study NCT ID: NCT03647488
Status: COMPLETED
Last Update Posted: 2022-01-24
First Post: 2018-08-20
Brief Title: Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Sponsor: Novartis Pharmaceuticals
Organization: Novartis
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Carcinoma Non-Small-Cell Lung
Keywords:
Name View
docetaxel View
Non-small-cell lung carcinoma View
Non-small-cell lung cancer View
NSCLC View
epidermal growth factor receptor wild type View
EGFRwt View
Anaplastic lymphoma kinase negative View
ALK- View
INC280 View
capmatinib and spartalizumab View
combination therapy View